Regulus Therapeutics

Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis

June 6, 2011

Research Article Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis Katey J. Rayner, Frederick J. Sheedy, Christine C. Esau, Farah N. Hussain, Ryan E. Temel, Saj Parathath, Janine M. van Gils, Alistair J. Rayner, Aaron N. Chang, Yajaira Suarez, Carlos Fernandez-Hernando, Edward A. Fisher, Kathryn J. Moore J. Clin. Invest. [...]

Read the full article →

Recent microRNA Press

September 3, 2010

Rosetta Genomics to Host Second Quarter 2010 Conference Call on Wednesday, September 8, 2010 REHOVOT, Israel & PHILADELPHIA, Sep 02, 2010 (BUSINESS WIRE) – Rosetta Genomics, Ltd. , a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that the Company will release financial results for the three and six months ended June [...]

Read the full article →

A Busy Month in the Business of microRNA

June 30, 2010

BUSINESSWIRE – June 29th – Alnylam Obtains Approvals to Initiate Phase I Study with ALN-TTR01 in Patients with TTR-Mediated Amyloidosis (ATTR) June 29th – Mirna Therapeutics Publishes Data Demonstrating In Vivo Proof of Concept for miR-34a microRNA Replacement Therapy in Cancer June 28th – Reimbursement for Rosetta Genomics’ miRview™ mets Test Now Available in Israel [...]

Read the full article →

microRNA Clinical News

March 29, 2010

Regulus Therapeutics and Collaborators Publish Pre-clinical In Vivo Efficacy Data on microRNA Therapeutics targeting microRNA-10b in Models of Breast Cancer Metastasis March 29, 2010 8:00 AM EDT – New Paper Published in Nature Biotechnology Reports Therapeutic Efficacy of Targeting miR-10b as a New Anti-Metastatic Agent – CARLSBAD, Calif.–(BUSINESS WIRE)– Regulus Therapeutics Inc. today announced the [...]

Read the full article →

microRNA Deal Struck

February 25, 2010

Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to … MarketWatch (press release)‎ Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA … Market Report — In Play (GSK) MSN Money GlaxoSmithKline and Regulus Therapeutics establish new collaboration to develop and commercialize microRNA Therapeutics Targeting miR-122 [...]

Read the full article →

Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21

January 25, 2010

Business Wire 1/25/09 The newly allowed claims cover miR-21, a microRNA that has been linked to a variety of diseases, including cancer, fibrosis, and heart disease. The claims additionally encompass single-stranded and double-stranded antisense compounds complementary to miR-21. The allowance of this second Tuschl III patent in the U.S. extends the scope of this patent [...]

Read the full article →

Upcoming Webcast – MicroRNA: The Year in Review

December 9, 2009

CARLSBAD, Calif., Dec. 9 /PRNewswire/ — Regulus Therapeutics Inc. will host an educational Webinar featuring a discussion with leading microRNA scientists: Tom Tuschl, Ph.D. Professor at Rockefeller University and Markus Stoffel, M.D., Ph.D. Professor at the Swiss Federal Institute of Technology. Dr. Tuschl will discuss the discovery of microRNA and its role as a master [...]

Read the full article →

Alnylam Pharmaceuticals & Regulus Therapeutics in the News

November 12, 2009

11/12/09 – CAMBRIDGE, Mass.–( Business Wire)–Alnylam Pharmaceuticals, Inc. an RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the “Investors” section of the company’s website at www.alnylam.com. Alnylam’s R&D Day will be held on Thursday, November 12, 2009 from 8:30 a.m. to 12:00 p.m. ET Alnylam scientists and management [...]

Read the full article →

Next Entries →